MONTREAL, June 16 /CNW Telbec/ - Haemacure Corporation (TSX : HAE), a
Montreal-based specialty bio-therapeutics company developing high-value human
plasma-derived protein products for commercialization, announces that it has
raised $7.8 million through the exercise of amended Series B warrants and
broker warrants issued as part of the private placement concluded in January
"I sincerely thank our shareholders who demonstrated their strong support
by exercising their warrants. We now have the financial resources to execute
on all of the necessary milestones to get our fibrin sealant into the clinic
in Q1-09. This financing significantly reduces the financial risk. All of our
time and attention will be focused on execution and getting a green light from
the FDA to enter clinical trials." said Joseph Galli, Chairman and CEO of
On June 4th, Haemacure began fractionating plasma in its new facility in
Sarasota, Florida. It is on-schedule and on-budget to produce fibrin sealant
clinical lots during Q3-08 and to file an amendment to its existing IND with
the U.S. FDA during Q4-08.
Haemacure's fractionation facility is the first and only U.S.-based
manufacturing facility for fibrin sealant destined for the U.S. market and
this is of significant strategic value.
Fibrin Sealant Pivotal Clinical Trials
The safety of Haemacure's lead product candidate, all-human fibrin
sealant, was demonstrated in past clinical trials as no serious adverse events
related to the product were reported. The efficacy of the product was also
significantly superior to the standard of care used in the control group.
New Preclinical Study in Adhesion Prevention
Encouraged by the positive results of the preclinical study Haemacure
conducted on the efficacy of its all-human fibrin sealant in preventing the
formation of post-surgical adhesions, Haemacure will sponsor a second study
for the same application, in a slightly different model.
Haemacure is currently pursuing business development opportunities in six
market segments where fibrin sealant has application, beyond its core
haemostasis segment. These are wound management, adhesion prevention,
regenerative medicine, drug delivery, in combination with biomaterials, and
cosmetics. All these segments represent major growth opportunities that
Haemacure will leverage.
Haemacure is pursuing strategic partnerships for the development of the
proteins it has identified in one of its two plasma fractions: albumin,
alpha-1 anti-trypsyn, immunoglobulin and plasminogen.
Haemacure Corporation is a specialty bio-therapeutics company developing
high-value human plasma-derived protein products for commercialization.
Haemacure's research and development effort is driven by its proprietary
plasma protein extraction technology to develop next-generation products,
including surgical hemostats. Haemacure's lead product candidate,
Hemaseel(R)HMN, is a fibrin sealant to enter pivotal Phase II/Phase III
clinical trials during the first quarter of 2009. Haemacure's second product
candidate is thrombin, a component of its fibrin sealant, now in preclinical
stage. Follow-on development will focus on surgical hemostats, wound healing,
adhesion prevention, regenerative medicine, drug delivery and combinations
with biomaterials. Haemacure has discovered eleven additional specialty
proteins and enzymes in one of its two plasma fractions and seeks to advance
these proteins and enzymes through partnerships with pharmaceutical and
biotechnology companies. Haemacure operates a manufacturing facility in
Sarasota, Florida through a wholly-owned subsidiary. The Corporation is traded
under stock symbol HAE on the TSX.
Certain of the statements contained in this news release are
forward-looking statements. Such statements, based as they are on the current
expectations of management, inherently involve numerous risks and
uncertainties, known and unknown. Some examples of known risks are: the impact
of general economic conditions, general conditions in the biotech industry,
changes in the regulatory environment in the jurisdictions in which Haemacure
does business, stock market volatility, fluctuations in costs, and changes to
the competitive environment due to consolidation or otherwise. Consequently,
actual future results may differ materially from the anticipated results
expressed in the forward-looking statements. Haemacure disclaims any intention
or obligation to update these statements.
For further information:
For further information: Haemacure Corporation: Joseph Galli, Chairman
and CEO, (514) 990-7074, email@example.com; Diane Roch, Director,
Communications, (514) 282-3350 ext. 27, Cell: (514) 952-3350,
firstname.lastname@example.org; Gilles Lemieux, Secretary, (514) 282-3350 ext. 22, Cell:
(514) 968-1382, email@example.com; www.haemacure.com